Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Trial Details

NCT ID
NCT04068597
Phase
PHASE1 / PHASE2
Sponsor
CellCentric Ltd.
Status
RECRUITING
Cancer Type
Non-Hodgkin Lymphoma Lymphoma
Interventions
  • CCS1477
  • Pomalidomide
  • Dexamethasone
  • Azacitidine
  • Venetoclax
  • Bortezomib
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Bethesda, Maryland, United States|38.98067,-77.10026
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Provision of consent
  • ECOG performance status 0-2
  • Patients with confirmed (per standard disease specific diagnostic criteria), relapsed or refractory haematological malignancies (NHL, MM and AML)
  • Must have previously received standard therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →